Coronavirus in Argentina: 39 deaths and 4,681 infections confirmed in the last 24 hours

With these data, the cumulative total number of cases since the beginning of the pandemic is 8,985,836, while deaths total 127,334

Guardar
A healthcare worker takes a
A healthcare worker takes a swab sample from a man to be tested for the coronavirus disease (COVID-19) as people line in the background to be tested, in Buenos Aires, Argentina January 6, 2022. Argentina broke its record for COVID-19 infections on Wednesday, approaching 100,000 daily cases as it faces a third wave of the pandemic. REUTERS/Agustin Marcarian

The Ministry of Health of the Nation reported this Wednesday, March 16, 2022 that, in the last 24 hours, 39 deaths from coronavirus and 4,681 new infections were recorded. With these data, the cumulative total number of cases since the beginning of the pandemic is 8,985,836, while deaths total 127,334.

This morning, the Buenos Aires Minister of Health, Nicolás Kreplak, said that students will stop wearing masks in the classrooms of schools in the province in the event that there is no increase in cases of coronavirus during April, when temperatures are expected to drop. He also stressed that no increase in infections was detected with the beginning of classes.

If we see that after the cold weeks the coronavirus does not increase again, we are going to talk about removing the masks from the classrooms; we are going to analyze the entire month of April because in March we are good, if April remains the same, it can be proposed,” said Kreplak in statements in dialogue with FM Urbana Play radio .

In reviewing the epidemiological situation in relation to classes, the minister specified that there was no impact on the increase in cases of COVID-19, which he attributed to care measures, such as classroom ventilation and the use of a mask. He also warned that “we will have to see when the cold comes”.

Kreplak said that removing masks from classrooms will be evaluated if coronavirus cases do not increase

Although for this new school year the “bubbles” were eliminated in schools, the health portfolio calls for the correct use of masks from all students from the first grade, teachers and non-teachers. Likewise, it is recommended to maintain social distance and cross-ventilation in the establishments and regular hand hygiene.

In turn, the Government of Buenos Aires incorporated 33,000 carbon dioxide sensors to monitor the air in enclosed spaces and provided masks to schools.

Regarding vaccination, the minister specified that, in the province of Buenos Aires, 94% of the population has applied the first dose and more than 84% the second dose.

“The third dose has been increasing but in recent weeks the speed has slowed down. It is important to go to get vaccinated and get the second and third doses,” Kreplak said, saying that “the risk” will come when the cold comes. “Don't be late,” he said. He also recalled that people who have some risk because of their age or health and have already taken all three doses, can access a fourth dose four weeks after the previous one.

In the province of Buenos Aires, 94% of the population has applied the first dose and more than 84% have the second dose (EFE/Juan Ignacio Roncoroni)

Since the start of the vaccination campaign, Argentina received more than 112 million vaccines against COVID-19. Of that total, 102,876,090 were sent to the provinces and 5,083,000 were donated to other countries.

According to the latest official data, until the last update, the total number of inoculations applied amounts to 95,310,114, of which 40,526,118 correspond to the first dose, 36,729,155 to the second, 3,038,293 were additional and another 15,016,548 were booster doses.

In recent days, the Ministry of Health has authorized the application of the Moderna vaccine for children aged 6 to 11 years, thus adding to that of Sinopharm and Pfizer among those who have the guarantee to be applied to that age group.

In a statement, the portfolio led by Carla Vizzotti specified that the decision is based on the analysis carried out by the National Institute of Medicines based on the clinical evidence that demonstrates the feasibility of its application.

KEEP READING:

Guardar